Candriam S.C.A. Celldex Therapeutics, Inc. Transaction History

Candriam S.C.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$22.61 - $40.65 $113,050 - $203,250	-5,000 Reduced 1.55%	317,509 $12.6 Million
Q3 2023 Nov 13, 2023	SELL	$25.45 - $37.46 $5.8 Million - $8.54 Million	-228,000 Reduced 41.42%	322,509 $8.88 Million
Q2 2023 Aug 08, 2023	SELL	$30.29 - $38.28 $1.36 Million - $1.72 Million	-45,000 Reduced 7.56%	550,509 $18.7 Million
Q1 2023 May 12, 2023	BUY	$34.78 - $47.43 $3.72 Million - $5.08 Million	107,000 Added 21.9%	595,509 $21.4 Million
Q4 2022 Feb 13, 2023	BUY	$27.78 - $45.38 $1.94 Million - $3.18 Million	70,000 Added 16.73%	488,509 $21.8 Million
Q3 2022 Nov 10, 2022	BUY	$22.7 - $37.57 $2.9 Million - $4.8 Million	127,715 Added 43.92%	418,509 $11.8 Million
Q2 2022 Aug 03, 2022	BUY	$20.5 - $37.33 $272,916 - $496,974	13,313 Added 4.8%	290,794 $7.84 Million
Q1 2022 May 13, 2022	SELL	$27.64 - $39.32 $3.03 Million - $4.31 Million	-109,740 Reduced 28.34%	277,481 $9.45 Million
Q4 2021 Feb 10, 2022	BUY	$35.68 - $56.27 $7.39 Million - $11.6 Million	206,999 Added 114.86%	387,221 $15 Million
Q3 2021 Nov 09, 2021	SELL	$28.95 - $55.99 $6.35 Million - $12.3 Million	-219,463 Reduced 54.91%	180,222 $9.73 Million
Q2 2021 Jul 20, 2021	BUY	$20.71 - $35.37 $1.15 Million - $1.96 Million	55,546 Added 16.14%	399,685 $13.4 Million
Q4 2020 Jan 22, 2021	BUY	$14.99 - $22.75 $5.16 Million - $7.83 Million	344,139 New	344,139 $6.03 Million

199

65.9M

1.68M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.15B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.